Morgan Stanley
FATE icon

Morgan Stanley’s Fate Therapeutics FATE Stock Holding History

Morgan Stanley’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$921K Sell
767,748
-149,198
-16% -$182K ﹤0.01% 5183
2025
Q4 		$901K Sell
916,946
-12,998
-1% -$15.6K ﹤0.01% 5236
2025
Q3 		$1.17M Sell
929,944
-1,503,631
-62% -$1.62M ﹤0.01% 5101
2025
Q2 		$2.73M Buy
2,433,575
+193,517
+9% +$225K ﹤0.01% 4510
2025
Q1 		$1.77M Sell
2,240,058
-582,125
-21% -$713K ﹤0.01% 4682
2024
Q4 		$4.66M Sell
2,822,183
-241,238
-8% -$608K ﹤0.01% 4061
2024
Q3 		$10.7M Sell
3,063,421
-84,568
-3% -$329K ﹤0.01% 3376
2024
Q2 		$10.3M Buy
3,147,989
+82,200
+3% +$360K ﹤0.01% 3297
2024
Q1 		$22.5M Buy
3,065,789
+423,077
+16% +$2.62M ﹤0.01% 2562
2023
Q4 		$9.88M Buy
2,642,712
+1,213,296
+85% +$2.86M ﹤0.01% 3929
2023
Q3 		$3.03M Buy
1,429,416
+152,584
+12% +$505K ﹤0.01% 4090
2023
Q2 		$6.08M Buy
1,276,832
+14,657
+1% +$80.9K ﹤0.01% 3619
2023
Q1 		$7.19M Sell
1,262,175
-475,900
-27% -$2.87M ﹤0.01% 3448
2022
Q4 		$17.5M Buy
1,738,075
+368,354
+27% +$6.92M ﹤0.01% 2474
2022
Q3 		$30.7M Sell
1,369,721
-254,548
-16% -$7.35M ﹤0.01% 1750
2022
Q2 		$40.3M Buy
1,624,269
+392,467
+32% +$10.8M 0.01% 1564
2022
Q1 		$47.8M Sell
1,231,802
-399,274
-24% -$15.5M 0.01% 1332
2021
Q4 		$95.4M Buy
1,631,076
+570,835
+54% +$32.4M 0.01% 928
2021
Q3 		$62.8M Buy
1,060,241
+110,468
+12% +$8.67M 0.01% 1143
2021
Q2 		$82.4M Sell
949,773
-257,724
-21% -$20.8M 0.01% 971
2021
Q1 		$99.6M Buy
1,207,497
+234,903
+24% +$22.5M 0.01% 764
2020
Q4 		$88.4M Buy
972,594
+690,286
+245% +$42.9M 0.01% 785
2020
Q3 		$11.3M Buy
282,308
+79,211
+39% +$2.77M ﹤0.01% 1923
2020
Q2 		$6.97M Sell
203,097
-56,234
-22% -$1.68M ﹤0.01% 2321
2020
Q1 		$5.76M Sell
259,331
-332,127
-56% -$8.4M ﹤0.01% 2321
2019
Q4 		$11.6M Buy
591,458
+383,992
+185% +$6.1M ﹤0.01% 2261
2019
Q3 		$3.22M Sell
207,466
-62,957
-23% -$1.21M ﹤0.01% 3346
2019
Q2 		$5.49M Buy
270,423
+149,080
+123% +$2.69M ﹤0.01% 2826
2019
Q1 		$2.13M Sell
121,343
-247,123
-67% -$3.9M ﹤0.01% 3529
2018
Q4 		$4.73M Buy
368,466
+157,543
+75% +$2.2M ﹤0.01% 2978
2018
Q3 		$3.44M Sell
210,923
-156,021
-43% -$1.85M ﹤0.01% 3555
2018
Q2 		$4.16M Buy
366,944
+140,293
+62% +$1.55M ﹤0.01% 3358
2018
Q1 		$2.21M Sell
226,651
-292,411
-56% -$2.8M ﹤0.01% 3908
2017
Q4 		$3.17M Sell
519,062
-62,175
-11% -$277K ﹤0.01% 3577
2017
Q3 		$2.3M Sell
581,237
-52,707
-8% -$179K ﹤0.01% 3738
2017
Q2 		$2.05M Buy
633,944
+22,298
+4% +$85.4K ﹤0.01% 3765
2017
Q1 		$2.78M Buy
611,646
+54,615
+10% +$200K ﹤0.01% 3502
2016
Q4 		$1.4M Buy
557,031
+556,862
+329,504% +$1.49M ﹤0.01% 4206
2016
Q3 		$1K Sell
169
-861
-84% -$2.09K ﹤0.01% 6418
2016
Q2 		$2K Sell
1,030
-18,972
-95% -$34.4K ﹤0.01% 6363
2016
Q1 		$36K Buy
20,002
+15,002
+300% +$30.9K ﹤0.01% 5732
2015
Q4 		$17K Sell
5,000
-4,626
-48% -$19.4K ﹤0.01% 6083
2015
Q3 		$52K Buy
9,626
+1,569
+19% +$10.7K ﹤0.01% 5714
2015
Q2 		$52K Buy
+8,057
New +$48.2K ﹤0.01% 5838
2015
Q1 		– Sell
-4,035
Closed -$20K – 6574
2014
Q4 		$20K Sell
4,035
-5,200
-56% -$22.9K ﹤0.01% 6048
2014
Q3 		$47K Buy
+9,235
New +$53.4K ﹤0.01% 5748
2014
Q2 		– Sell
-349
Closed -$3K – 6535
2014
Q1 		$3K Buy
+349
New +$2.7K ﹤0.01% 6306

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley's FATE Position: Q1 2026 in Review

Morgan Stanley reduced its Fate Therapeutics (FATE) stake by 16% in Q1 2026, selling an estimated $182K and leaving 767,748 shares worth $921K. The position accounts for ﹤0.01% of the portfolio, ranked #5183.

Morgan Stanley first reported a position in FATE in Q1 2014 and has held it in 47 quarters since. The position peaked at $99.6M in Q1 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Morgan Stanley held 767,748 shares of Fate Therapeutics worth $921K as of Q1 2026.
  • Morgan Stanley sold 149,198 Fate Therapeutics shares in Q1 2026, an estimated $182K.
  • Fate Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5183 holding.
  • Morgan Stanley first reported a position in Fate Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • Morgan Stanley's Fate Therapeutics position peaked at $99.6M in Q1 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.